DCPH
Price
$25.46
Change
+$0.01 (+0.04%)
Updated
May 16, 6:59 PM EST
77 days until earnings call
PAHC
Price
$17.98
Change
-$0.27 (-1.48%)
Updated
May 16, 6:59 PM EST
104 days until earnings call
Ad is loading...

DCPH vs PAHC

Header iconDCPH vs PAHC Comparison
Open Charts DCPH vs PAHCBanner chart's image
Deciphera Pharmaceuticals
Price$25.46
Change+$0.01 (+0.04%)
Volume$748.18K
CapitalizationN/A
Phibro Animal Health
Price$17.98
Change-$0.27 (-1.48%)
Volume$50.23K
CapitalizationN/A
View a ticker or compare two or three
DCPH vs PAHC Comparison Chart

Loading...

DCPHDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PAHCDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
DCPH vs. PAHC commentary
May 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DCPH is a Buy and PAHC is a Hold.

COMPARISON
Comparison
May 17, 2024
Stock price -- (DCPH: $25.45 vs. PAHC: $18.25)
Brand notoriety: DCPH and PAHC are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DCPH: 47% vs. PAHC: 96%
Market capitalization -- DCPH: $1.27B vs. PAHC: $523.71M
DCPH [@Pharmaceuticals: Other] is valued at $1.27B. PAHC’s [@Pharmaceuticals: Other] market capitalization is $523.71M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DCPH’s FA Score shows that 0 FA rating(s) are green whilePAHC’s FA Score has 2 green FA rating(s).

  • DCPH’s FA Score: 0 green, 5 red.
  • PAHC’s FA Score: 2 green, 3 red.
According to our system of comparison, PAHC is a better buy in the long-term than DCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DCPH’s TA Score shows that 5 TA indicator(s) are bullish while PAHC’s TA Score has 6 bullish TA indicator(s).

  • DCPH’s TA Score: 5 bullish, 5 bearish.
  • PAHC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PAHC is a better buy in the short-term than DCPH.

Price Growth

DCPH (@Pharmaceuticals: Other) experienced а +0.32% price change this week, while PAHC (@Pharmaceuticals: Other) price change was +6.23% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.14%. For the same industry, the average monthly price growth was +37.19%, and the average quarterly price growth was +19330.38%.

Reported Earning Dates

DCPH is expected to report earnings on Aug 01, 2024.

PAHC is expected to report earnings on Aug 28, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+1.14% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for DCPH with price predictions.
OPEN
A.I.dvisor published
a Summary for PAHC with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
DCPH($1.27B) has a higher market cap than PAHC($524M). PAHC (58.994) and DCPH (57.781) have similar YTD gains . PAHC has higher annual earnings (EBITDA): 83.7M vs. DCPH (-208.86M). DCPH has more cash in the bank: 306M vs. PAHC (92.5M). DCPH has less debt than PAHC: DCPH (25.9M) vs PAHC (513M). PAHC has higher revenues than DCPH: PAHC (982M) vs DCPH (163M).
DCPHPAHCDCPH / PAHC
Capitalization1.27B524M243%
EBITDA-208.86M83.7M-250%
Gain YTD57.78158.99498%
P/E RatioN/A34.11-
Revenue163M982M17%
Total Cash306M92.5M331%
Total Debt25.9M513M5%
FUNDAMENTALS RATINGS
DCPH vs PAHC: Fundamental Ratings
DCPH
PAHC
OUTLOOK RATING
1..100
4916
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
14
Undervalued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
9783
PRICE GROWTH RATING
1..100
3536
P/E GROWTH RATING
1..100
1007
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for DCPH (65) in the Biotechnology industry. This means that PAHC’s stock grew somewhat faster than DCPH’s over the last 12 months.

DCPH's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as PAHC (100) in the Pharmaceuticals Major industry. This means that DCPH’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's SMR Rating (83) in the Pharmaceuticals Major industry is in the same range as DCPH (97) in the Biotechnology industry. This means that PAHC’s stock grew similarly to DCPH’s over the last 12 months.

DCPH's Price Growth Rating (35) in the Biotechnology industry is in the same range as PAHC (36) in the Pharmaceuticals Major industry. This means that DCPH’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's P/E Growth Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for DCPH (100) in the Biotechnology industry. This means that PAHC’s stock grew significantly faster than DCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DCPHPAHC
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
71%
Declines
ODDS (%)
Bearish Trend 22 days ago
81%
Bearish Trend 16 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bearish Trend 1 day ago
69%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
DCPHDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PAHCDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AUUAX21.430.24
+1.13%
AB Select US Equity A
RIGBX38.710.32
+0.83%
American Funds Intl Gr and Inc R2
SLSSX11.800.09
+0.77%
Selected International S
CHDVX14.590.11
+0.76%
Cullen High Dividend Equity I
APDGX23.02N/A
N/A
Artisan Global Value Advisor

DCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DCPH has been loosely correlated with PAHC. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DCPH jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DCPH
1D Price
Change %
DCPH100%
+0.04%
PAHC - DCPH
53%
Loosely correlated
+0.22%
ACET - DCPH
39%
Loosely correlated
+5.26%
SCYX - DCPH
29%
Poorly correlated
+14.72%
SNDL - DCPH
29%
Poorly correlated
-1.91%
ALKS - DCPH
28%
Poorly correlated
-1.43%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with DCPH. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then DCPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+0.22%
DCPH - PAHC
53%
Loosely correlated
+0.04%
EGRX - PAHC
41%
Loosely correlated
-1.28%
PBH - PAHC
36%
Loosely correlated
-7.01%
SUPN - PAHC
32%
Poorly correlated
-0.79%
ELAN - PAHC
31%
Poorly correlated
-0.18%
More